| 引用本文: | 李嘉玮,张玲娜,路玉媛,沈路凡,寇雨顺,兰雪艳,滕政杰,伊琳.中医药靶向微小RNA干预心肌缺血再灌注损伤研究进展[J].中国现代应用药学,2026,43(7):128-139. |
| LI Jiawei,ZHANG Lingna,LU Yuyuan,SHEN Lufan,KOU Yushun,LAN Xueyan,TENG Zhengjie,Yilin.Progress of Chinese medicine targeted microRNA intervention in myocardial ischemia-reperfusion injury research[J].Chin J Mod Appl Pharm(中国现代应用药学),2026,43(7):128-139. |
|
| |
|
|
| 本文已被：浏览 13次 下载 2次 |
码上扫一扫！ |
|
|
| 中医药靶向微小RNA干预心肌缺血再灌注损伤研究进展 |
|
李嘉玮1, 张玲娜1, 路玉媛1, 沈路凡1, 寇雨顺1, 兰雪艳1, 滕政杰2, 伊琳1
|
|
1.甘肃中医药大学中西医结合学院;2.甘肃中医药大学附属医院
|
|
| 摘要: |
| 心肌缺血再灌注损伤(Myocardial ischemia reperfusion injury,MIRI)是心肌梗死后血流恢复再灌注时诱发的进一步心肌损害,其涉及多种复杂的细胞及分子机制,已成为影响心血管疾病患者预后转归的严重并发症之一,目前在临床上尚缺乏有效的防治措施。微小RNA(microRNA,miRNA)具有靶向细胞分化、凋亡、自噬、氧化应激及能量代谢障碍的能力,被视为多种疾病的生物标志物,近些年来,随着相关研究不断深入,发现越来越多的miRNA对MIRI的发生发展起着关键调控作用。中医药治疗MIRI具有多靶点、多层次的优势,本文归纳梳理了miRNA对MIRI的相关调控通路及效应,并分析了中药单体、复方及中成药通过靶向miRNA对MIRI的治疗成果及分子机制,以期为实现中医药治疗MIRI基础研究转化及拓展临床思路提供参考。 |
| 关键词: 心肌缺血再灌注损伤 微核糖核酸 中医药 综述 |
| DOI： |
| 分类号: |
| 基金项目:2022年国家自然科学基金基于lncRNA探讨武威汉简“瘀方”对高血压肾损伤的保护作用机制及网络药理学研究”(82160842)；甘肃省联合科研基金一般项目武威汉简“瘀方”对高血压肾损伤的保护作用研究(23JRRA1521)；2023甘肃省中医药科研项目武威汉简“瘀方”对自发性高血压大鼠肠道菌群的影响及机制研究(GZKP-2022-40)；敦煌医学于转化教育部重点实验室开放课题大泻肺汤对心力衰竭的干预作用研究(DHYX23-07)；2025年度甘肃中医药大学研究生“创新创业基金”项目(2025CXCY-012).通讯作者:*伊琳,博士生导师,教授,主要从事中西医结合防治心血管疾病研究,E-mail：yilin@gszy.edu.cn |
|
| Progress of Chinese medicine targeted microRNA intervention in myocardial ischemia-reperfusion injury research |
|
LI Jiawei1, ZHANG Lingna1, LU Yuyuan1, SHEN Lufan1, KOU Yushun1, LAN Xueyan1, TENG Zhengjie2, Yilin1
|
|
1.College of Integrative Medicine,Gansu University of Traditional Chinese Medicine;2.Affiliated Hospital of Gansu University of Traditional Chinese Medicine
|
| Abstract: |
| Myocardial ischemia reperfusion injury (MIRI) is further myocardial damage induced when blood flow is restored to reperfusion after myocardial infarction, which involves a variety of complex cellular and molecular mechanisms, and has become one of the serious complications affecting the prognosis and regression of patients with cardiovascular diseases. Currently, there is a lack of effective preventive and curative measures in clinical practice. MicroRNA (miRNA) has the ability to target cell differentiation, apoptosis, autophagy, oxidative stress and energy metabolism disorders, and is regarded as a biomarker for many diseases. In recent years, with the deepening of related research, more and more miRNAs have been found to play a key role in the regulation of the development of MIRI. Chinese medicine treatment of MIRI has the advantages of multi-targets and multi-levels. In this paper, we summarized the relevant regulatory pathways and effects of miRNAs on MIRI, and analyzed the therapeutic results and molecular mechanisms of Chinese medicine monomers, compound formulas and proprietary Chinese medicines on MIRI by targeting miRNAs, with a view to providing references to realize the translation of basic research on the treatment of MIRI by Chinese medicine and expanding the clinical ideas. |
| Key words: myocardial ischemia-reperfusion injury microRNA traditional Chinese medicine review |
|
|
|
|
